MarginsXMarginsX
Home › Markets › Health Care › BIIB

Biogen Inc. (BIIB)

BIIB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$251.65
-0.69% on the day
Market cap
$37.2B
Large cap
Revenue · 2025
$9.9B
+2.2% on 2024
Net income · 2025
$1.3B
13.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/0000875045-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBIIB on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000875045
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$9.9B
Net income$1.3B
Operating incomeNot in SEC XBRL data
Net margin13.1%
Operating marginOperating income not reported
Revenue growth+2.2%
Cash$3.0B
Total assets$29.4B
P/E (computed)28.8×
P/S (computed)3.8×

Warning signs

Cash runway
Cash-flow positive
$1.3B cash at September 30, 2026
Share count, 1 year
+0.8%
2025-10-29 to 2026-10-26 · +2.0% over 3 years
Going-concern doubt
No
10-Q filed October 28, 2026
Insider net buying, 12 months
-$905K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-28
Cash and burn$1.3B cash; operating cash flow $561.8M a quarter.Report 2026-09-30
Shares outstanding147,820,223 (2026-10-26); 146,702,272 a year earlier; 144,898,112 three years earlier.Cover page 2026-10-26
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-02-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $585, sold $905K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$2.8B-$20.6M$640.8M$1.3B$7.3B$10.3B10-Q 2026-10-28
Q2 2026
2026-06-30
$2.7B$97.5M$448.9M$1.3B$7.3B$10.0B10-Q 2026-07-29
Q1 2026
2026-03-31
$2.5B$319.5M$645.5M$3.4B$6.3B$9.9B10-Q 2026-04-29
Q4 2025
2025-12-31
$2.3B-$48.9M$511.9M$3.0B$6.3B$9.9B10-K 2026-02-06
Q3 2025
2025-09-30
$2.5B$466.5M$1.3B$3.9B$6.3B$10.1B10-Q 2026-10-28
Q2 2025
2025-06-30
$2.6B$634.8M$160.9M$2.8B$6.3B$10.0B10-Q 2026-07-29
Q1 2025
2025-03-31
$2.4B$240.5M$259.3M$2.6B$4.5B$9.8B10-Q 2026-04-29
Q4 2024
2024-12-31
$2.5B$266.7M$760.9M$2.4B$4.5B$9.7B10-K 2026-02-06

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22025-05-08
Latest annual report10-K2026-02-06
Latest quarterly / interim10-Q2026-10-28
Latest current report8-K2026-10-28
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.0%
1 month+10.7%
3 months+20.3%
Year to date+44.0%
1 year+53.8%
From 52-week high-0.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
RVMDRevolution Medicines Inc.$166.87-3.15%$36.1B
ARGXargenx SE$950.95-0.95%$59.0B
BNTXBioNTech SE American Depositary Share$85.26-0.40%$21.4B
NBIXNeurocrine Biosciences Inc.$165.31-1.25%$16.7B
EXELExelixis Inc.$67.10-2.75%$16.4B
MRNAModerna Inc.$215.27-3.63%$87.1B
TECHBio-Techne Corp$72.79-0.01%$11.4B
HALOHalozyme Therapeutics Inc.$96.50-3.76%$11.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier